๐ ๐๐ซ๐ ๐๐๐ง๐ข๐ฌ๐ฌ๐
โข Q2 external revenue: CHF 309.7M (+15.2%)
โข Q2 revenue: CHF 295.4M (+16.1%)
โข Rx external revenue in Germany: +45.8%
โข Non-Rx external revenue: +6.7%
โข Digital Services: +80.0%
โข Active customers: 12.9M (+1.1M YoY)
โ
๐ฏ ๐๐ฎ๐ฌ๐๐ฅ๐ข๐๐ค
โข Impact of the strong first half of the year and the AI-First strategy on guidance will be presented on August 19
โข EBITDA breakeven in the course of 2026 remains the focus
โ
๐ Key Highlights
โข Rx growth accelerates to +45.8%, up 17.2% from Q1
โข Digital Services grow by 80% thanks to TeleClinic, Retail Media, and the marketplace
โข Revenue from Germany rises by 15.1%; revenue from Europe by 5.5%
โข Adjusted EBITDA is expected to improve further compared to Q1
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ-๐๐ฎ๐ฌ๐ฌ๐๐ ๐
โOur revenue momentum picked up noticeably again in the second quarter of 2026. The acceleration in Rx sales to 45.8 percent and the significant increase in new Rx customers underscore that we are achieving sustainable growth in the strategically important prescription business.โ